Sodio valproato ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
144Lennox-Gastaut syndrome1

144. Lennox-Gastaut syndrome


Clinical trials : 101 Drugs : 68 - (DrugBank : 12) / Drug target genes : 49 - Drug target pathways : 60
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-023505-36-IT
(EUCTR)
29/09/201105/01/2012A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than 4 years of age with Inadequately Controlled Lennox-Gastaut SyndromeA Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to less than 4 years of age with Inadequately Controlled Lennox-Gastaut Syndrome - E2080-G000-303 Lennox Gastaut Syndrome
MedDRA version: 14.1;Level: PT;Classification code 10048816;Term: Lennox-Gastaut syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Inovelon
Other descriptive name: Rufinamide oral suspension
INN or Proposed INN: lamotrigine
Other descriptive name: Lamictal
INN or Proposed INN: sodio valproato
INN or Proposed INN: topimarato
Other descriptive name: topimarate
EISAI LTD UKNULLNot RecruitingFemale: yes
Male: yes
75Greece;Italy